Holen Sie sich die Stockscreener-App
1.70
1.73%
-0.03
Handel nachbörslich:
1.71
0.01
+0.59%
Schlusskurs vom Vortag:
$1.73
Offen:
$1.7
24-Stunden-Volumen:
756.13K
Relative Volume:
0.57
Marktkapitalisierung:
$131.92M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.6538
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
-0.58%
1M Leistung:
+31.78%
6M Leistung:
+74.43%
1J Leistung:
+81.02%
1-Tages-Spanne:
$1.66
$1.73
1-Wochen-Bereich:
$1.63
$1.89
52-Wochen-Spanne:
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
Firmenname
Coherus Oncology Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Vergleichen Sie CHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.70 | 201.07M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-16 | Herabstufung | UBS | Buy → Neutral |
| 2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
What technical patterns form on Coherus Oncology Inc. (8C5) stock chartsMarket Sentiment Review & Weekly Return Optimization Plans - newser.com
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
How strong dollar benefits Coherus Oncology Inc. (8C5) stockJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Why Coherus Oncology Inc. (8C5) stock is trending on social mediaJuly 2025 Market Mood & High Accuracy Trade Signal Alerts - newser.com
Published on: 2025-10-06 04:13:27 - newser.com
How Coherus Oncology Inc. (8C5) stock reacts to monetary easingJuly 2025 Review & Low Drawdown Trading Strategies - newser.com
Published on: 2025-10-05 03:27:37 - newser.com
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Coherus Oncology Announces Upcoming Presentation of CHS-114 Data at SITC 2025 Annual Meeting - Quiver Quantitative
Coherus Oncology Announces Poster Presentation at the 40th - GlobeNewswire
Selective intratumoral Treg depletion — Coherus Oncology's CHS-114 at SITC Nov 8; Webinar Oct 22 - Stock Titan
Published on: 2025-10-03 06:30:25 - newser.com
Will Coherus BioSciences Inc. outperform the marketMarket Risk Analysis & Low Risk High Reward Trade Ideas - newser.com
Published on: 2025-10-03 05:08:55 - newser.com
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Coherus BioSciences at UBS Virtual Oncology Day: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Coherus Oncology: Five Readouts Or More Possible In 2026 - Seeking Alpha
Published on: 2025-10-01 05:00:35 - newser.com
What dividend safety rating applies to Coherus Oncology Inc. (8C5) stockMarket Risk Summary & Weekly Momentum Stock Picks - newser.com
What analysts say about Coherus Oncology Inc 8C5 stockStock Screening Results & Free Gain Edge With Data - earlytimes.in
Coherus Oncology Inc 8C5 Stock Analysis and ForecastEconomic Indicators Overview & Small Budget Wealth Tips - Early Times
Strs Ohio Acquires Shares of 324,000 Coherus Oncology, Inc. $CHRS - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat
3 Promising Penny Stocks With Market Caps At Least $100M - simplywall.st
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Coherus Oncology Inc (NASDAQ: CHRS) Rises 7.09% In Recent Trading, What’s Next? - stocksregister.com
Coherus Oncology, Inc. $CHRS Shares Sold by State of Wyoming - Defense World
Coherus BioSciences at H.C. Wainwright: Strategic Shift to Immuno-Oncology - Investing.com
Coherus BioSciences at H.C. Wainwright: Strategic Shift to Immuno-Oncology By Investing.com - Investing.com Canada
Maxim Group Upgrades Coherus Oncology (NASDAQ:CHRS) to "Buy" - MarketBeat
Coherus BioSciences at Baird Conference: Oncology Focus Amid Asset Sales - Investing.com
Coherus Biosciences Regains Nasdaq Compliance - The Globe and Mail
Coherus Oncology regains Nasdaq compliance after meeting minimum bid price - Investing.com
Coherus Oncology (NASDAQ:CHRS) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Rating Upgraded by Maxim Group - Defense World
Maxim Group Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
Maxim Group upgrades Coherus Biosciences stock to Buy on oncology pivot By Investing.com - Investing.com South Africa
Maxim Group upgrades Coherus Biosciences stock to Buy on oncology pivot - Investing.com Canada
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Coherus Oncology (CHRS) Receives Upgrade from Maxim Group | CHRS Stock News - GuruFocus
Maxim Group Upgrades Coherus Oncology to Buy, Sets PT at $4 - AInvest
RSI Reset May Fuel Rebound in Coherus BioSciences Inc.July 2025 Sector Moves & Technical Pattern Recognition Alerts - beatles.ru
Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Finanzdaten der Coherus Oncology Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):